Waters Corporation introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters Intact Mass app on waters connect allows scientists using the BioAccord LC-MS System to confirm the mass of biomolecules and impurities made by synthetic or recombinant processes nearly twice as fast as other commercially available options.

“Acquiring mass and purity data of biomolecules is time-consuming. Skilled analysis of complex mass spectrometry data is required, typically in remote specialist analytical laboratories,” said Jon Pratt, Waters Division Senior Vice President, Waters Corporation. “The new Waters Intact Mass App enables bioengineers and biochemists to accelerate drug discovery and development with simplified technology to generate mass confirmation data on their own in minutes/hours instead of days/weeks.”

Intact mass analysis is routinely performed during all stages of the development of biological drugs including proteins, peptides, oligonucleotide therapies and conjugates. In early stages of drug discovery, biochemists must analyze hundreds or even thousands of different samples per week. To help speed this process, the Waters Intact Mass app provides a fast, reliable, and automated solution to facilitate mass confirmation and purity determination of novel biotherapeutics. The application features intelligent automated deconvolution to process sample results within minutes of their capture, with minimal user input.